StuffbyNainax drug recall: MR. 7 SUPER 700000 capsules
Key facts
- Agency
- U.S. Food and Drug Administration (FDA)
- Program
- Drugs
- Classification
- Class I
- Status
- Ongoing
- Event ID
- 98256
- Recall initiated
- Dec 15, 2025
- Classified by FDA
- Mar 18, 2026
- Posted in Enforcement Report
- Mar 11, 2026
- Recalling firm
- StuffbyNainax
- Firm location
- Huntsville, TX, United States
- Initiated by
- Voluntary: Firm initiated
- Firm notified customers by
- Press Release
- Products in this event
- 1
What to do
Compare the product, lot or serial numbers below with what you have. If you use a prescription drug or medical device in this recall, talk to your pharmacist or health care provider before you stop using it, and follow the firm's instructions.
Reason for recall
Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadalafil
What the classification means
- Class I: FDA's most serious category: there is a reasonable probability that using or being exposed to the product will cause serious health problems or death.
About this recall
The firm started this recall on Dec 15, 2025. FDA classified it 93 days later, on Mar 18, 2026. Distribution reported by FDA: Product was distributed to 4 customers in the US.
Recalled products (1)
D-0397-2026 Class I Ongoing
MR. 7 SUPER 700000 capsules, 1 capsule blister card, Distributed by mR. 7
Codes / lots: All codes; Exp 12/31/2029
Quantity: 4
Source and freshness
- Source
- U.S. Food and Drug Administration (FDA) Enforcement Report, via the openFDA drug enforcement dataset
- Official notice
- FDA Enforcement Report, event 98256
- Raw record
- openFDA API (JSON)
- Dataset last updated by FDA
- Nov 3, 2026
- Imported by RecallRadar
- Nov 4, 2026
Enforcement Report entries describe recalls FDA has classified. They are not always the same as a company press release. If something here differs from FDA's record, FDA's record is correct — please tell us.